Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Queensland Health
Argus Health
Covington
Cantor Fitzgerald
Boehringer Ingelheim

Generated: May 26, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,173,037

« Back to Dashboard

Which drugs does patent 7,173,037 protect, and when does it expire?

Patent 7,173,037 protects ADEMPAS and is included in one NDA.

This patent has forty-five patent family members in thirty-five countries.

Summary for Patent: 7,173,037
Title:Carbamate-substituted pyrazolopyridines
Abstract: The present invention relates to compounds which stimulate soluble guanylate cyclase, to the preparation thereof and to the use thereof as medicaments, in particular as medicaments for the treatment of cardiovascular disorders and/or sexual dysfunction.
Inventor(s): Alonso-Alija; Cristina (Haan, DE), Bischoff; Erwin (Wuppertal, DE), Munter; Klaus (Wulfrath, DE), Stasch; Johannes-Peter (Solingen, DE), Stahl; Elke (Gladbach, DE), Weigand; Stefan (Wuppertal, DE), Feurer; Achim (Wilhelmsfeld, DE)
Assignee: Bayer HealthCare AG (Leverkusen, DE)
Application Number:10/513,869
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,173,037
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 7,173,037
Patent Claim Types:
see list of patent claims
Compound; Process; Composition; Use;

Drugs Protected by US Patent 7,173,037

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bayer Hlthcare ADEMPAS riociguat TABLET;ORAL 204819-001 Oct 8, 2013 RX Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Bayer Hlthcare ADEMPAS riociguat TABLET;ORAL 204819-002 Oct 8, 2013 RX Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Bayer Hlthcare ADEMPAS riociguat TABLET;ORAL 204819-003 Oct 8, 2013 RX Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Bayer Hlthcare ADEMPAS riociguat TABLET;ORAL 204819-004 Oct 8, 2013 RX Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Bayer Hlthcare ADEMPAS riociguat TABLET;ORAL 204819-005 Oct 8, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,173,037

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany102 20 570May 8, 2002
PCT Information
PCT FiledApril 25, 2003PCT Application Number:PCT/EP03/04304
PCT Publication Date:November 20, 2003PCT Publication Number: WO03/095451

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Moodys
Colorcon
Fish and Richardson
Medtronic
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.